 | Up a level |
Laznickova, A; Laznicek, M; Trejtnar, F; Maecke, H R; Eisenwiener, K P; Reubi, J C (2010). Biodistribution of two octreotate analogs radiolabeled with indium and yttrium in rats. Anticancer research, 30(6), pp. 2177-84. Kapandriti: International Inst. of Anticancer Research
Cordier, D; Forrer, F; Bruchertseifer, F; Morgenstern, A; Apostolidis, C; Good, S; Müller-Brand, J; Mäcke, H; Reubi, J C; Merlo, A (2010). Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. European journal of nuclear medicine and molecular imaging, 37(7), pp. 1335-44. Berlin: Springer 10.1007/s00259-010-1385-5
Melis, M; Forrer, F; Capello, A; Bijster, M; Bernard, B F; Reubi, J C; Krenning, E P; De Jong, M (2007). Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [(177)Lu-DOTA(0),Tyr(3)]octreotate therapy. Quarterly journal of nuclear medicine and molecular imaging, 51(4), pp. 324-33. Torino: Minerva Medica
Laissue, J A; Chappuis, B B; Müller, C; Reubi, J C; Gebbers, J-O (1993). The intestinal immune system and its relation to disease. Digestive diseases, 11(4-5), pp. 298-312. Karger 10.1159/000171421
